NKTR Financial Facts
Total operating costs and expenses: 69.24MResearch and development: 51.95M
See Full Income Statement
Other long-term liabilities: 5.52M
Total liabilities: 492.95M
See Full Balance Sheet
Nektar Therapeutics (NKTR) Earnings
|
Expand Research on NKTR
| Next EPS Date | 8/6/26 | EPS Growth Rate | +96.4% |
|---|---|---|---|
| Average EPS % Beat Rate | -322.5% | Revenue Growth Rate | +141.7% |
| Average % Move 1-Wk after EPS | +4.1% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
8/6/26  |
Q226 | N/A | -$0.10 | N/A | N/A | $27M | N/A | N/A | N/A | ||
| 5/7/26 | Q126 | -$1.82 | $0.00 | -$1.82 | $10.9M | N/A | N/A |  | | Details | |
| 3/12/26 | Q425 | -$1.78 | $0.00 | -$1.78 | $21.81M | N/A | N/A | | | Details | |
| 11/6/25 |
Q325 | N/A | -$0.19 | N/A | N/A | $9.84M | N/A | N/A | N/A | ||
| 11/6/25 | Q325 | $1.85 | $0.00 | +$1.85 | $11.79M | N/A | N/A | | | Details | |
| 8/7/25 | Q225 | -$2.78 | -$0.20 | -$2.58 | $11.17M | $9.74M | N/A | | | Details | |
| 5/8/25 | Q125 | -$0.24 | -$0.16 | -$0.08 | $10.5M | $16.31M | N/A | | | Details | |
| 3/12/25 | Q424 | $0.03 | -$0.16 | +$0.19 | $29.2M | $29.81M | N/A | | | Details |
